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Background and purpose: Excessive production of nitric oxide (NO) by inducible NO synthase (iNOS) is thought to underlie
the vascular dysfunction, systemic hypotension and organ failure that characterize endotoxic shock. Plasma levels of atrial
natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are raised in animal models and
humans with endotoxic shock and correlate with the associated cardiovascular dysfunction. Since both NO and natriuretic
peptides play important roles in cardiovascular homeostasis via activation of guanylate cyclase-linked receptors, we used mice
lacking natriuretic peptide receptor (NPR)-A (NPR1) to establish if natriuretic peptides contribute to the cardiovascular
dysfunction present in endotoxic shock.
Experimental approach: Wild-type (WT) and NPR-A knockout (KO) mice were exposed to lipopolysaccharide (LPS) and
vascular dysfunction (in vitro and in vivo), production of pro-inflammatory cytokines, and iNOS expression and activity were
evaluated.
Key results: LPS-treated WT animals exhibited a marked fall in mean arterial blood pressure (MABP) whereas NPR-A KO mice
maintained MABP throughout. LPS administration caused a greater suppression of vascular responses to the thromboxane-
mimetic U46619, ANP, acetylcholine and the NO-donor spermine-NONOate in WT versus NPR-A KO mice. This differential
effect on vascular function was paralleled by reduced pro-inflammatory cytokine production, iNOS expression and activity
(plasma [NOx] and cyclic GMP).
Conclusions and implications: These observations suggest that NPR-A activation by natriuretic peptides facilitates iNOS
expression and contributes to the vascular dysfunction characteristic of endotoxic shock. Pharmacological interventions that
target the natriuretic peptide system may represent a novel approach to treat this life-threatening condition.
British Journal of Pharmacology (2010) 160, 2045–2054; doi:10.1111/j.1476-5381.2010.00830.x
Keywords: atrial natriuretic peptide; inducible nitric oxide synthase; cyclic GMP; endotoxaemia; hypotension; vascular smooth
muscle
Abbreviations: ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide; eNOS,
endothelial nitric oxide synthase; ET-1, endothelin-1; IFNg, interferon-g; IL, interleukin; iNOS, inducible nitric
oxide synthase; KO, knockout; L-NMA, NG-methyl-L-arginine; LPS, lipopolysaccharide; MABP, mean arterial
blood pressure; NO, nitric oxide; NOS, nitric oxide synthase; [NOx], total [NO2-] + [NO3-]; NPR-A, natriuretic
peptide receptor-A (NPR1); SPER-NO, spermine-NONOate; TNFa, tumour necrosis factor-a; U46619, 9,11-
dideoxy-9a,11a-methanoepoxy prostaglandin F2a; WT, wild-type
Introduction
Endotoxic shock is a systemic inflammatory syndrome in
which vascular smooth muscle and endothelial dysfunction
contribute to a progressive failure of the circulation to provide
blood to vital organs with consequent hypotension, multiple
organ failure and death (Hotchkiss and Karl, 2003). The con-
dition remains a major cause of death in intensive care
patients with 30–60% of individuals failing to recover (Singer,
2006). Whilst considerable progress has been made in under-
standing the molecular and cellular mechanisms underlying
the pathogenesis of endotoxic shock, little advance has been
achieved in terms of therapy (Singer, 2006). Thus, identifica-
tion and characterization of novel pathways contributing to
disease progression could prove significant in reducing the
associated mortality and morbidity.
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Animal models and patient studies have confirmed a
central role for excessive nitric oxide (NO) production by
inducible nitric oxide synthase (iNOS) in the development of
endotoxic shock. Under physiological conditions iNOS is
effectively absent; however, in response to pro-inflammatory
cytokines and bacterial lipopolysaccharide (LPS, endotoxin),
iNOS is expressed in several cell types resulting in a ‘high-
output’ NO production. Although NO is essential for combat-
ing infection, excessive NO production during inflammatory
episodes results in NO-mediated host damage (MacMicking
et al., 1997). In particular, endothelial and smooth muscle
dysfunction result in a dramatic decrease in blood pressure
due to increased NO-mediated dilatation and hyporeactivity
to catecholamines (Julou-Schaeffer et al., 1990; Fleming et al.,
1992). In accord, selective iNOS inhibitors restore blood pres-
sure and reduce mortality in experimental animal models of
sepsis (Kilbourn et al., 1990; Petros et al., 1994; Rees et al.,
1998) and iNOS knockout (KO) mice are resistant to LPS-
induced vascular dysfunction (Hollenberg et al., 2000;
Chauhan et al., 2003). A role for iNOS in the pathogenesis of
endotoxic shock has also been established in humans. For
instance, total plasma nitrite (NO2-) and nitrate (NO3-; NOx)
levels (an index of NO production) and iNOS expression are
significantly elevated in endotoxic patients compared to
healthy individuals (Ochoa et al., 1991; Annane et al., 2000).
Despite these animal and human data advocating the use of
iNOS inhibitors in the treatment of endotoxic shock, clinical
trials with the non-selective NOS inhibitor NG-methyl-L-
arginine (L-NMA) have shown no beneficial effect on survival
(Lopez et al., 2004). Therefore, new therapeutic targets that
can reverse the cardiovascular dysfunction associated with
endotoxic shock may offer a valuable alternative.
Atrial natriuretic peptide (ANP), a key cardiovascular
homeostatic hormone (Ahluwalia et al., 2004), plays a role in
regulating inflammation and modulates iNOS expression in a
number of cell types in vitro (Marumo et al., 1995; Vollmar
and Schulz, 1995). Several studies have alluded to a potential
role for natriuretic peptides (particularly ANP and B-type
natriuretic peptide, BNP) in the pathogenesis of endotoxic
shock, although a definitive function has yet to be estab-
lished. Intravenous injection of LPS in rodents causes a rise in
plasma ANP concentrations and a reduction in plasma
volume (Aiura et al., 1995). This is also true in humans with
endotoxic shock, in whom plasma ANP and BNP levels are
significantly elevated (Witthaut et al., 2003). Furthermore,
ANP and BNP concentrations in the circulation are increased
in cardiovascular diseases such as heart failure, which is a
common complication of sepsis (Potter et al., 2006). Indeed,
in an experimental model of ovine sepsis, selective blockade
of the natriuretic peptide receptor A and B (NPR-A/B) by
HS-142-1 reverses many indices of myocardial depression
associated with the condition (Hinder et al., 1997; Stubbe
et al., 2004). Hence, it has been proposed that ANP and cyclic
GMP (cGMP) (the intracellular second messenger responsible
for mediating the biological activity of ANP) could be markers
of severe and fatal myocardial depression early in the course
of human endotoxic shock (Hartemink et al., 2001). In com-
bination, these in vitro and in vivo data hint at a role for
natriuretic peptides in the vascular abnormalities associated
with endotoxic shock. However, little is known about the
relationship between natriuretic peptides, iNOS and the vas-
cular dysfunction characteristic of this condition.
To address this deficit, we used NPR-A (NPR1) KO mice (the
principal receptor mediating the biological actions of ANP
and BNP) to explore the role of natriuretic peptides in regu-
lating iNOS expression and activity in the context of (cardio)
vascular dysfunction during endotoxic shock in vitro and in
vivo.
Methods
Reagents were obtained from Sigma (St. Louis, MO, USA)
unless stated otherwise. All experiments were performed in
accordance with the Animals (Scientific procedures) Act 1986.
Drug and receptor nomenclature conforms to the ‘Guide to
receptors and ion channels’ (Alexander et al., 2008).
LPS treatment and tissue homogenization
Salmonella typhimurium LPS (Poole, Dorset, UK; 12.5 mg·kg-1,
i.v.) or vehicle (physiological saline, sodium chloride 0.9%
w/v, Ivex Pharmaceuticals, Antrim, Northern Ireland) were
administered to male NPR-A KO mice [kind gift of Prof O.
Smithies, University of North Carolina, Chapel Hill, NC, USA
(Oliver et al., 1997)] or littermate controls (25–30 g) via the
tail vein. After 16 h animals were killed by cervical dislocation
and tissues and blood collected. Tissues were snap frozen in
liquid nitrogen and stored at –80°C. They were then homog-
enized using an ice-cold mortar and pestle, transferred to
whole cell homogenization buffer (50 mM Tris-HCl, 150 mM
NaCl, 1% Triton X-100, 2 mM EDTA, 8 mM EGTA, protease
inhibitor cocktail tablet; Roche, Burgess Hill, UK) and incu-
bated on ice with vortexing every 10 min for a minimum of
30 min. Samples were centrifuged at 16 060¥ g for 15 min at
4°C and the supernatant was retained for subsequent analysis.
Blood samples were centrifuged at 16 060¥ g for 5 min at
room temperature and plasma retained for nitrate/nitrite,
cGMP and cytokine determination.
Measurement of mean arterial blood pressure
Mean arterial blood pressure (MABP) was measured in chroni-
cally instrumented, conscious male NPR-A KO or WT mice as
we have described previously (Connelly et al., 2005). After the
mice had recovered from surgery (24 h), resting MABP was
measured for 24 h on a pre-calibrated PowerLab system
(ADInstruments, Castle Hill, New South Wales, Australia);
24 h later, LPS (12.5 mg·kg-1) was administered via the jugular
vein and the MABP monitored over a further 16 h period.
Functional reactivity
Male NPR-A KO or WT mice were treated with LPS or vehicle
as described above. After 16 h the animals were killed by
cervical dislocation and the thoracic aortae were carefully
excised, cleaned of connective tissue and mounted in 10 mL
organ baths for isometric tension recordings, as described
previously (Hussain et al., 1999). Following equilibration, an
EC80 concentration of the thromboxane-mimetic, U46619
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(Biomol International, Exeter, UK) was added to the organ
bath and once a stable contraction was attained, cumulative
concentration-response curves to ACh (1 nM–10 mM), ANP
(0.01 nM–1 mM), the NO donor SPER-NO (Calbiochem, Not-
tingham, UK; 1 nM–100 mM) and the adenylyl cyclase activa-
tor forskolin (Calbiochem; 1 nM–100 mM) were obtained. The
concentration of U46619 used to pre-contract the vessels
from NPR-A KO and LPS-treated animals was carefully titrated
to match the contractile response in control tissues. Data were
captured using PowerLab and Chart version 5 (AD Instru-
ments, Oxfordshire, UK).
Western blot analysis
Determination of iNOS expression by immunoblot was
achieved as we have described previously (Connelly et al.,
2005), using a primary anti-iNOS antibody (BD Biosciences,
Cowley, Oxford UK; 1:2000 dilution) and a secondary horse-
radish peroxidise-conjugated goat anti-rabbit IgG antibody
(Dako, Cambridge UK; 1:1000 dilution). Bands were quanti-
fied by densitometry using AlphaImager (Alpha Innotech, San
Leandro, CA, USA).
Plasma NOx, cytokine and cGMP measurements
Plasma samples were analysed for NO2- and NO3- using
chemiluminesence as we have described previously (Connelly
et al., 2005). A BioPlex® (Bio-Rad, Hemel Hempstead, UK)
array was used to determine cytokine production in response
to LPS in the plasma of WT and NPR-A KO mice according to
the
manufacturer’s instructions. Plasma cGMP concentrations
were measured using a specific ELISA (R & D Systems,
Abingdon, UK).
Data analysis
All statistical analyses were performed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). Densitometric
analyses were performed using AlphaEaseFC (Alpha Inno-
tech). All data are plotted graphically as mean values, with
vertical bars representing standard error of the mean. Stu-
dent’s t-test or one-way analysis of variance (ANOVA) followed
by Bonferroni’s multiple comparison test was used to assess
differences between individual experimental conditions. Two-
way ANOVA was used to compare temporal changes in MABP
in WT and NPR-A KO animals. A probability (P) value of <0.05
was taken as an appropriate level of significance.
Results
Haemodynamic profile in WT and NPR-A KO mice in response
to LPS
The resting MABP in the WT and NPR-A KO animals was
113.9  2.9 and 131.6  2.5 mmHg, respectively. These
values are consistent with previous studies reporting
increased blood pressure in NPR-A-deficient mice (Oliver
et al., 1997). Administration of LPS (12.5 mg·kg-1; i.v.) caused
a slow decline in the MABP inWT animals such that there was
a mean reduction of 11.5  0.8 mmHg over 16 h (Figure 1), in
accord with previous findings (Connelly et al., 2005; Vo et al.,
2005). In NPR-A KO animals, following administration of LPS
(12.5 mg·kg-1; i.v.) there was little or no deviation in blood
pressure over a 16 h period (Figure 1), such that the MABP was
not significantly different from the initial value
(D2.6  0.9 mmHg). Interestingly, following administration
of LPS there was a small, rapid decrease in MABP in both WT
and NPR-A KO animals (Figure 1), consistent with endothelial
NOS (eNOS) activation, as we and others have reported (Con-
nelly et al., 2005; Vo et al., 2005).
Effect of NPR-A gene deletion on plasma NOx and cGMP in
response to LPS
Administration of LPS (12.5 mg·kg-1; i.v.) led to an increase in
plasma NOx concentration, as expected in animals with
endotoxic shock (Connelly et al., 2005; Vo et al., 2005);
however, levels were significantly lower in NPR-A KO mice in
comparison to WT animals (Figure 2). NOx levels were indis-
tinguishable between saline-treated NPR-A KO and WT
animals (Figure 2). Accordingly, plasma cGMP levels were
raised in response to LPS, but this increase was significantly
smaller in NPR-A KO animals compared to WT controls
(Figure 2).
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Figure 1 Change in mean arterial blood pressure (MABP) in WT and NPR-A KO mice treated with LPS (12.5 mg·kg-1) or saline (both i.v.) for
16 h. Data are represented as mean  standard error of the mean, n = 9; *P < 0.05 versus WT (across the whole time period). WT, wild-type;
KO, knockout; NPR-A, natriuretic peptide receptor-A; LPS, lipopolysaccharide.
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Effect of NPR-A gene deletion of plasma cytokine levels in
response to LPS
Administration of LPS (12.5 mg·kg-1; i.v.) led to an increase in
the plasma concentrations of interleukin (IL)-1b, IL-10, inter-
feron (IFN)g and tumour necrosis factor (TNF)a (Figure 3), but
not IL-2, IL-4 and IL-5 (data not shown). However, plasma
levels of IL-1a, IFNg and TNFa were all significantly lower in
NPR-A KO animals, whereas the plasma concentration of
IL-10 was markedly increased in these mice (Figure 3).
Effect of NPR-A deletion on iNOS expression in response to LPS
There was no detectable iNOS expression in tissues from
saline-treated WT or NPR-A KO mice. Administration of LPS
(12.5 mg·kg-1; i.v.) for 16 h led to an increase in the expres-
sion of iNOS protein in lung and aorta of WT and NPR-A KO
mice. However, in tissues from NPR-A KO mice there was a
significantly lower level of iNOS protein detected (lung:
–38.5  6.3%, aorta: –80.3  10.2%; Figure 4), that paralleled
the reduced levels of plasma NOx, cGMP and pro-
inflammatory cytokines (Figures 2 and 3).
Ex vivo pharmacology
Since treatment of NPR-A KO mice with LPS resulted in dra-
matically reduced iNOS expression and plasma NOx, cGMP
and pro-inflammatory cytokine levels in comparison to WT
animals, functional pharmacological studies were conducted
using thoracic aortae from saline (volume-matched) or LPS
(12.5 mg·kg-1; both i.v.,16 h)-treated NPR-A KO and WT mice
to assess the effect of NPR-A deficiency on the vascular dys-
function associated with endotoxaemia.
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Figure 2 Plasma NOx (A) and cGMP (B) levels in WT and NPR-A KO mice treated with LPS (12.5 mg·kg-1) or saline (both i.v.) for 16 h. Data
are represented as mean  standard error of the mean, n = 7; *P < 0.05 versus corresponding saline control, #P < 0.05 versus LPS-treated WT.
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Figure 3 Plasma IL-1b (A), IFNg (B), TNFa (C) and IL-10 (D) in WT and NPR-A KO mice treated with LPS (12.5 mg·kg-1) or saline (both i.v.)
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(1) Effect of NPR-A deletion on vascular responses to U46619
following LPS. U46619 caused a concentration-dependent
contraction in tissues from both WT and NPR-A KO mice. In
WT aortae, in vivo LPS treatment caused a small but significant
rightward shift in the concentration-response curve toU46619
(pEC50: 7.69  0.12 and 7.94  0.05; P < 0.05; LPS and saline,
respectively; Figure 5). In contrast, in tissues from NPR-A KO
mice LPS treatment had no significant effect on responses to
U46619 compared to control (pEC50: 6.41  0.16 and
7.12  0.18; P > 0.05; LPS and saline, respectively; Figure 5).
(2) Effect of NPR-A deletion on vascular responses to ANP following
LPS. In order to explore the effects of LPS on relaxant
responses, tissues were pre-contracted with an approximate
EC80 of U46619 that was titrated to account for the altered
potency between aortae from WT and NPR-A KO animals.
Tissues from WT mice treated with LPS exhibited a significant
rightward shift in the concentration-response curve to ANP
(pEC50: 7.89  0.20 and 8.13  0.13; P < 0.05; LPS and saline,
respectively; Figure 6) accompanied by a significant decrease
in Emax (Emax: 53.61  4.13 and 76.16  3.58; P < 0.05; LPS and
saline, respectively; Figure 6). Aortae from NPR-A KO animals
did not exhibit vasorelaxation in response to ANP, confirming
the lack of NPR-A in these animals (Figure 6).
(3) Effect of NPR-A deletion on vascular responses to ACh following
LPS. Treatment of WT animals with LPS caused a significant
rightward shift in the concentration-response curve to the
endothelium-dependent relaxant ACh (pEC50: 6.69  0.21
and 7.00  0.08; P < 0.05; LPS and saline, respectively;
Figure 7) and a significant decrease in the maximum (Emax:
25.46  2.11 and 66.36  2.22; P < 0.05; LPS and saline,
respectively; Figure 7). Vessels from LPS-treated NPR-A KO
mice showed almost complete restoration of the responsive-
ness to ACh when compared to WT animals treated with LPS
(pEC50: 6.70  0.24 and 7.30  0.28; LPS and saline, respec-
tively; Figure 7). Furthermore, the Emax was indistinguishable
in LPS and saline-treated NPR-A KO mice (Emax: 77.31  6.92
and 79.58  6.93; P > 0.05; LPS and saline, respectively;
Figure 7).
(4) Effect of NPR-A deletion on vascular responses to SPER-NO
following LPS. Treatment of WT mice with LPS caused a
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significant rightward shift in the concentration response
curve to the NO donor SPER-NO (pEC50: 5.08  0.16 and
5.86  0.07; P < 0.05; LPS and saline, respectively; Figure 8).
However, the Emax remained unchanged (Emax: 101.4  12.13
and 94.40  3.01; P > 0.05; LPS and saline, respectively;
Figure 8). This reduction in potency following LPS adminis-
tration was not observed in NPR-A KO animals where the
curves were superimposable (pEC50: 5.25  0.12 and
5.42  0.18; Emax: 95.73  7.09 and 91.64  8.83; both
P > 0.05; LPS and saline, respectively; Figure 8).
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(5) Effect of NPR-A deletion on vascular responses to forskolin
following LPS. In order to confirm that the vascular dysfunc-
tion observed in WT and NPR-A KO mice following LPS treat-
ment was restricted to cGMP (and not cAMP)-dependent
pathways, concentration-response curves to the adenylate
cyclase activator, forskolin, were constructed. As expected
from previous studies (Hussain et al., 1999; Sabrane et al.,
2003; Madhani et al., 2006) the vasorelaxant potency to for-
skolin was identical in LPS and saline-treated WT and NPR-A
KO animals (Figure 9).
Discussion
This study demonstrates that NPR-A activation (by ANP
and/or BNP) plays a key role in facilitating pro-inflammatory
cytokine production, iNOS expression/activity and the subse-
quent development of vascular hyporeactivity in LPS-induced
murine shock. In NPR-A KO animals treated with LPS in vivo,
circulating levels of the pro-inflammatory cytokines IL-1b,
IFNg and TNFa, iNOS expression and activity (as assessed by
plasma NOx and cGMP accumulation), endothelial and vas-
cular smooth muscle dysfunction, and systemic hypotension
are all significantly reduced in comparison to WT animals; in
contrast, plasma concentrations of the anti-inflammatory
cytokine IL-10 are significantly elevated. These findings give
rise to the thesis that blockade of natriuretic peptide signal-
ling may represent a novel therapeutic target that would
prevent the (cardio)vascular hyporeactivity that underlies the
high mortality associated with this condition.
Endotoxic shock remains a major cause of death worldwide.
Despite a more detailed understanding of many aspects of
disease progression, this has not yet translated into improved
therapy and reductions in mortality (Singer, 2006). As such,
identification of novel pathways contributing to the develop-
ment of this condition may offer potential for superior treat-
ment regimens. Inducible NOS is well-established to play a
pivotal role in the development of the (cardio)vascular
hyporeactivity, which characterizes endotoxic shock and is a
major cause of death in patients with this condition (Petros
et al., 1994; Chauhan et al., 2003). High-output NO produc-
tion by this isoform of NOS results in both hypo-
responsiveness to vasoconstrictors and endothelial
dysfunction, which combine to elicit a marked systemic
hypotension. In accord with this schema, iNOS KO mice and
selective iNOS inhibitors have proven effective in restoring
the vascular dysfunction associated with endotoxic shock
(Julou-Schaeffer et al., 1990; Kilbourn et al., 1994; MacMick-
ing et al., 1995; Chauhan et al., 2003). Disappointingly,
however, clinical trials of a non-selective NOS inhibitor
(L-NMA) in patients with septic shock have reported
increased, rather than decreased, mortality (Lopez et al.,
2004).
More recently, a key role for the endothelial isoform of
NOS, eNOS, in regulating the inflammatory response, particu-
larly iNOS expression and NO production during endotox-
aemia, has been described by ourselves and others (Connelly
et al., 2005; Vo et al., 2005). In this case, immediate activation
of eNOS (via an Akt- and PI3K-dependent phosphorylation)
by LPS results in a cGMP-mediated facilitation of iNOS expres-
sion and activity; accordingly, eNOS KO mice do not exhibit
hypotension and are resistant to endotoxaemia. Since plasma
levels of natriuretic peptides are raised in endotoxaemia
(Aiura et al., 1995; Witthaut et al., 2003), and these vasoactive
mediators play analogous cardiovascular homeostatic roles to
NO, via production of cGMP, we hypothesized that natriuretic
peptides might also play a key role in the pathogenesis of
endotoxic shock. Thus, we assessed whether ANP and/or BNP
signalling is important for the vascular dysfunction observed
during endotoxic shock by comparing the haemodynamic
profile of WT and NPR-A KO mice following exposure to LPS.
Both NPR-A KO and WT animals showed a small reduction in
systemic blood pressure within 1 h of exposure to LPS, which
is consistent with a rapid, transient activation of eNOS (Con-
nelly et al., 2005; Vo et al., 2005). The blood pressure rapidly
recovered and was maintained at basal levels in NPR-A KO
animals for the duration of the study. However, the blood
pressure of WT mice continued to drop steadily throughout
the remainder of the investigation; by the 18 h time point the
MABP had dropped by almost 30 mmHg. This improved hae-
modynamic profile in NPR-A KO animals demonstrates that a
lack of NPR-A conveys resistance to the vascular dysfunction
characteristic of endotoxic shock. This phenomenon is likely
to result from both direct and indirect consequences of NPR-A
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deficiency. Firstly, increased levels of natriuretic peptides (i.e.
ANP and BNP) occurring during endotoxic shock would not
be able to mediate their direct vasodilator activity via this NPR
subtype nor stimulate excretion of fluid (and salt; i.e. natri-
uresis) to lower blood volume. Secondly, natriuretic peptides
facilitate pro-inflammatory cytokine production and iNOS
expression via a NPR-A- and cGMP- dependent mechanism
(akin to NO). Indeed, the regulation of pro-inflammatory
gene expression, particularly iNOS, by cGMP-dependent
mechanisms has been previously documented (Choi et al.,
1999; Perez-Sala et al., 2001; Connelly et al., 2003; Connelly
et al., 2005; Gunnett et al., 2005; Vo et al., 2005) and a
common pathway appears to be modulation of NFkB activity
(Traenckner et al., 1995; Kalra et al., 2000). Thus, it is likely
that similar downstream cGMP-triggered pathways underlie
the pro-inflammatory role for natriuretic peptides (via NPR-A
activation) in the pathogenesis of endotoxic shock. Whether
the regulation of iNOS expression is a direct effect of natri-
uretic peptides, or secondary to a NPR-A-driven increase in
pro-inflammatory cytokine production [e.g. IL-1b, TNFa IFNg;
each a potent stimulus for iNOS induction (Xie and Nathan,
1994)] remains to be elucidated. Regardless, this clear effect of
NPR-A gene deletion on the production of, and balance
between, pro- and anti-inflammatory cytokines suggests that
the natriuretic peptide family underpin a novel mechanism
governing host defence.
To examine this concept further, we investigated if the
observed haemodynamic responses in NPR-A KO animals
were paralleled by altered pro-inflammatory cytokine produc-
tion, iNOS expression, NO production and cGMP generation.
Plasma levels of the pro-inflammatory cytokines IL-1b, IFNg
and TNFa were all decreased in NPR-A KO versus WT animals
treated with LPS. Conversely, plasma concentrations of the
anti-inflammatory cytokine IL-10 were increased in NPR-A
KO animals when compared to WT mice. The balance in
favour of pro- versus anti-inflammatory cytokine production
was mirrored by increased expression of iNOS protein, and
enhanced production of NO and cGMP in WT versus NPR-A
KO animals. The dramatic reduction in iNOS expression and
activity correlated well with the haemodynamic changes fol-
lowing induction of endotoxic shock and confirm that NPR-A
KO animals exhibit a considerably smaller pro-inflammatory
response, paralleling the observations made in eNOS KO
animals (Connelly et al., 2005). This observation also fits with
a well-established role for IL-1b, IFNg and TNFa in facilitating
iNOS expression in numerous cell types (Xie and Nathan,
1994). Interestingly, there was almost complete abrogation of
iNOS expression in the lungs and aorta of NPR-A KO mice
treated with LPS, and vascular responsiveness to
endothelium-dependent and independent vasorelaxants was
normal. Yet, there was still a significant production of NOx
and cGMP, suggesting that iNOS activity accounts for ~50% of
the total NO/cGMP production during endotoxaemia.
Undoubtedly, eNOS activation in response to LPS (Connelly
et al., 2005; Vo et al., 2005), will contribute to the NO/cGMP
generation. However, NPR-A deficient animals also have an
intact CNP-NPR-B-cGMP system that may account for a pro-
portion of the remaining cGMP production; this is particu-
larly relevant since sepsis and pro-inflammatory cytokines
represent a strong stimulus for CNP release from the endot-
helium and sepsis is one of the few disorders in which plasma
CNP levels are raised (Suga et al., 1993; Hama et al., 1994).
Nonetheless, this ~50% reduction in plasma NOx/cGMP
levels observed in NPR-A KO mice in response to LPS is suffi-
cient to permit normal vascular function (i.e. MABP in vivo
and endothelial and smooth muscle function in vitro). This
suggests that there is a threshold of NO/cGMP production
within which vascular homeostasis, in particular endothelial
function, can be maintained effectively. Outside that, endot-
helial dysfunction occurs and there is inappropriate control of
local blood flow (and systemic blood pressure). In vivo, this
manifests as the systemic hypotension, reduced tissue perfu-
sion and end organ failure associated with sepsis.
Having established that NPR-A deletion alters the severity
of endotoxic shock in vivo, we examined whether the well-
established vascular dysfunction occurring in this condition
was alleviated in animals lacking this NPR subtype in vitro.
Contractile responses to the thromboxane mimetic U46619
were significantly (albeit marginally) reduced in tissues from
WT animals treated with LPS compared to WT controls. This
is consistent with an iNOS-dependent inhibition of the con-
tractile apparatus (Chauhan et al., 2003). However, respon-
siveness to U46619 in aortae from NPR-A KO mice was
equivalent in control and LPS-treated animals. Again, this fits
with a much reduced iNOS expression and activity in these
tissues. In aortae from WT animals, the potency of both ACh
(endothelium-dependent) and SPER-NO (endothelium-
independent) was significantly reduced following exposure to
LPS, whereas in tissues from NPR-A KO animals there was no
difference in dilator responsiveness in the absence or presence
of LPS. Such observations provide further evidence that the
diminished inflammatory response in NPR-A KO animals
during endotoxic shock results in the restoration of the
endothelial and smooth muscle dysfunction that lead to hae-
modynamic depression. It is also possible that endothelin
(ET)-1 release is up-regulated in WT versus NPR-A KO animals
challenged with LPS (Mansart et al., 2008; Scicluna et al.,
2008) resulting in a greater functional antagonism of vasodi-
lator activity. Notably, vascular responsiveness to the cAMP-
dependent dilator forskolin was not impaired, confirming
that vascular dysfunction is restricted to the cGMP signalling
cascade. We and others have previously demonstrated (Papa-
petropoulos et al., 1996; Hussain et al., 1999; Madhani et al.,
2003; Sabrane et al., 2003) that vascular responsiveness to NO
is exquisitely sensitive to the ambient NO and natriuretic
peptide concentrations. In the current study, the reduced
potency of ACh and SPER-NO illustrates the impaired endot-
helial production of NO and smooth muscle responsiveness,
respectively, during endotoxaemia. In tandem with the hypo-
responsiveness to the vasoconstrictor U46619, this entails
that not only is there a systemic hypotension, but that endot-
helial cells cannot regulate vascular tone and blood flow at a
local level, perhaps explaining the aberrant organ perfusion
that occurs in this condition. These impairments are not as
severe in NPR-A KO animals, resulting in an improved hae-
modynamic profile and vascular function.
In summary, results from the current study provide con-
vincing evidence that natriuretic peptides (principally ANP
and BNP), via NPR-A activation, play a role in the pathogen-
esis of endotoxic shock. Specifically, these vasoactive media-
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tors facilitate the expression of pro-inflammatory cytokines
and iNOS expression/activity, and augment the vascular dys-
function and detrimental haemodynamic profile associated
with this disease. Whilst these findings will need confirma-
tion in longer-term, more clinically representative models of
human sepsis, the data from the current model represent
interesting proof of concept studies that warrant further
investigation. Accordingly, inhibition of natriuretic peptide
release or bioactivity may provide a novel approach to allevi-
ating the haemodynamic problems associated with endotoxic
shock and to reduce the associated mortality.
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